不同病因急性脑梗死患者静脉溶栓治疗的疗效分析

doi:10.3969/j.issn.1673-5765.2020.05.008

摘要/Abstract

摘要：

目的比较不同病因脑梗死患者静脉溶栓早期疗效及出血转化风险，为不同病因脑梗死静脉溶栓治疗提供参考和依据。方法回顾性纳入2015年9月-2019年9月在深圳市人民医院神经内科住院接受rt-PA静脉溶栓的连续性急性脑梗死患者，收集患者的基线资料，并根据中国缺血性卒中分型（Chinese Ischemic Stroke Subclassification，CISS）标准进行病因分组。临床有效定义为溶栓后较溶栓前NIHSS评分下降≥4分或 NI HSS评分降至0分。分析不同病因患者静脉溶栓后24 h和7 d的有效率及24 h出血转化的风险。结果共纳入283例患者，静脉溶栓后24 h有效例数共129例（4 5.58%），其中穿支动脉疾病（penetrating artery disease，PAD）组35例（63.64%）、大动脉粥样硬化型（large-artery atherosclerosis， LAA）组70例（54.69%）、病因不确定（undetermined etiology，UE）组10例（45.45%）、其他病因（other etiology，OE）组3例（23.08%）、心源性（cardiogenic stroke，CS）组11例（16.92%）。组间比较，PAD组有效率明显高于UE组、OE组、CS组，P值分别为0.015、0.008、0.004；LAA组有效率明显高于UE组、OE组、 CS组，P值分别为0.032、0.011、0.009；UE组有效率明显高于OE组、CS组，P值分别为0.031、0.019。溶栓7 d有效例数共193例（68.20%），其中PAD组有效率明显高于CS组（72.73% vs 58.46%，P =0.009）。溶栓7 d后≤55岁患者有效率明显高于≥80岁患者（76.11% vs 55.56%，P =0.013）。共有23例出现出血转化（8.13%），PAD组出血转化率（1.82%）明显低于LAA组、OE组、UE组、CS组，P值分别为0.025、 0.018、0.004、0.001；CS组出血转化率（18.46%）明显高于LAA组、OE组、UE组，P值分别为0.005、 0.012、0.021；≥80岁患者出血转化率明显高于≤55岁患者（14.81% vs 6.19%，P =0.002）和55～79岁患者（14.81% vs 8.39%，P =0.006）。结论不同病因脑梗死患者早期溶栓有效率和出血转化风险有差异，穿支动脉疾病组溶栓早期有效率较高，出血转化风险低；心源性组患者早期有效率较低，出血转化风险相对较高；患者越年轻，溶栓效果越好，出血转化风险越小。

文章导读： 对于不同病因分型的急性脑梗死患者，rt-PA静脉溶栓后穿支动脉疾病患者疗效最好，心源性患者疗效最差；患者越年轻，溶栓疗效越好，出血转化风险越小。

关键词: 脑梗死; 静脉溶栓; 阿替普酶; CISS分型

Abstract:

Objective To evaluate the early effectiveness and risk of hemorrhagic transformation (HT) of intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS) of different causes. Methods AIS patients treated with intravenous thrombolysis using rt-PA in Department of Neurology of Shenzhen People's Hospital between September 2015 and September 2019 were retrospectively included in this analysis. All the patients were grouped according to the Chinese Ischemic Stroke Subclassification (CISS). Clinical effectiveness was defined as a decrease of NIHSS score ≥4 points or NIHSS score decreasing to 0 point. The outcome at 24 hours and 7 days

after thrombolysis and risk of HT at 24 hours after thrombolysis in different groups were analyzed. Results A total of 283 patients were included. The overall effective rate was 45.58% (n =129) at 24 hours after IVT, of which penetrating artery disease (PAD) group was 63.64% (n =35), large-artery atherosclerosis (LAA) group was 54.69% (n =70), undetermined etiology (UE) group was 45.45% (n =10), other etiology (OE) group was 23.08% (n =3), cardiogenic stroke (CS) group was 16.92% (n =11). Comparison among groups showed that the effective rate of PAD group were better than that of UE, OE and CS groups, and the P value was 0.015, 0.008 and 0.004, respectively; LAA group was better than UE, OE and CS group, and the P value was 0.032, 0.011 and 0.009, respectively; UE group was better than OE and CS groups, and the P value was 0.031and 0.019. The overall effective rate was 68.20% (n =193) at 7 days after IVT, and the effective rate of PAD group was better than that of CS group (72.73% vs 58.46%, P =0.009), the 7-day effective rate in patients under 55 years was better than that in patients over 80 years (76.11% vs 55.56%, P =0.013). HT occurred in 23 patients (8.13%), the HT rate of PAD group (1.82%) was lower than that of LAA, OE, UE and CS groups, the P value was 0.025, 0.018, 0.004 and 0.001, respectively; and the HT rate of CS group (18.46%) was higher than that of LAA, OE and UE groups, the P value was 0.005, 0.012 and 0.021, respectively. The HT rate of patients over 80 years was higher than that of patients under 55 years (14.81% vs 6.19%, P =0.002) and patients aged 55 to 79 (14.81% vs 8.39%, P =0.006). Conclusions The early thrombolytic effect and HT risk were different in AIS patients with different causes. PAD group had higher effective rate of thrombolysis and lower HT risk, while CS group had lower effective rate and relatively higher HT risk. The younger the patient, the better the thrombolysis effect and the lower the risk of HT.

Key words: Acute ischemic stroke; Intravenous thrombolysis; Alteplase; Chinese Ischemic Stroke Subclassification

蔡智立，何奕涛，付学军，邹良玉，李卓星，周致帆，陈思言，王倩，郭毅. 不同病因急性脑梗死患者静脉溶栓治疗的疗效分析[J]. 中国卒中杂志, 2020, 15(05): 504-509.

CAI Zhi-Li, HE Yi-Tao, FU Xue-Jun, ZOU Liang-Yu, LI Zhuo-Xing, ZHOU Zhi-Fan, CHEN Si-Yan, WANG Qian, GUO Yi. Clinical Analysis of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Different Causes[J]. Chinese Journal of Stroke, 2020, 15(05): 504-509.

参考文献

[1] WANG W Z，JIANG B，SUN H X，et al. Prevalence，

incidence，and mortality of stroke in China：results

form a nationwide population-based survey of 480 687

adults[J]. Circulation，2017，135（8）：759-771.

[2] 中华医学会神经病学分会，中华医学会神经病学分

会脑血管病学组. 中国急性缺血性脑卒中诊治指南

2018[J]. 中华神经科杂志，2018，51（9）：666-682.

[3] POWERS W J，RABINSTEIN A A，ACKERSON

T，et a1. 2018 guidelines for the early management of

patients with acute ischemic stroke：a guideline for healthcare professionals from the American Heart

Association/American Stroke Association[J/OL].

Stoke，2018，49（3）：e46-e99[2019-12-03].

https：//doi.org/10.1161/STR.0000000000000158.

[4] EMBERSON J，LESS K R，LYDEN P，et al. Effect

of treatment delay，age，and stroke severity on the

effects of intravenous thrombolysis with alteplase for

acute ischaemic stroke：a meta-analysis of individual

patient data from randomised trials[J]. Lancet，2014，

384（9958）：1929-1935.

[5] GAO S，WANG Y J，XU A D，et al. Chinese

ischemic stroke subclassification[J]. Front Neurol，

2011，2：6.

[6] National Institute of Neurological Disorders

and Stroke rt-PA Stroke Study Group. Tissue

plasminogen activator for acute ischemic stroke[J].

N Engl J Med，1995，333（24）：1581-1587.

[7] HACKE W，KASTE M，BLUHMKI E，et al.

Thrombolysis with alteplase 3 to 4.5 hours after

acute ischemic stroke[J]. N Engl J Med，2008，359

（13）：1317-1329.

[8] 蒋王乐，徐俊，徐耀，等. 穿支动脉疾病患者病情进

展相关因素的分析[J]. 中华老年心脑血管病杂志，

2017，19（9）：961-964.

[9] PETTY G W，BROWN R D Jr，WHISNANT J

P，et al. Ischemic stroke subtypes：a populationbased

study of survival，recurrence，and functional

outcome[J]. Neurology，2000，31（5）：1062-1068.

[10] ARBOIX A，MASSONS J，GARCÍA-EROLES L，

et al. Trends in clinical features and early outcome

in patients with acute cardioembolic stroke subtype

over a 19-year period[J]. Neurol India，2012，60（3）：

288-293.

[11] ANTICOLI S，BRAVI M C，PERILLO G，et al.

Effect of cardioembolic etiology on intravenous

thrombolysis efficacy for acute ischemic stroke[J].

Curr Neurovasc Res，2016，13（3）：193-198.

[12] PAN Y T，LEE J D，LIN Y H，et al. Comparisons

of outcomes in stroke subtypes after intravenous

thrombolysis[J]. Springerplus，2016，5：47.

[13] GRIEBE M，FISCHER E，KABLAU M，et al.

Thrombolysis in patients with lacunar stroke is safe：

an observational study[J]. J Neurol，2014，261（2）：

405-411.

[14] WANG X G，ZHANG L Q，LIAO X L，et al.

Unfavorable outcome of thrombolysis in Chinese

patients with cardioembolic stroke：a prospective cohort study[J]. CNS Neurosci Ther，2015，21（8）：

657-661.

[15] KIMURA K，IGUCHI Y，YAMASHITA S，et al.

Atrial fibrillation as an independent predictor for no

early recanalization after IV-t-PA in acute ischemic

stroke[J]. J Neurol Sci，2008，267（1-2）：57-61.

[16] VACLAVIK D，VILIONSKIS A，JATUZIS D，et

al. Clinical outcome of cardioembolic stroke treated

by intravenous thrombolysis[J]. Acta Neurol Scand，

2018，137（3）：347-355.

[17] FORLIVESI S，BOVI P，TOMELLERI G，et

al. Stroke etiologic subtype may influence the

rate of，hyperdense middle cerebral artery sign

disappearance after intravenous thrombolysis[J]. J

Thromb Thrombolysis，2017，43（1）：86-90.

[18] FRANK B，FULTON R，WEIMAR C，et al. Impact

of atrial fibrillation on outcome in thrombolyzed

patients with stroke：evidence from the Virtual

International Stroke Trials Archive（VISTA）[J].

Stroke，2012，43（7）：1872-1877.

[19] MOLINA C A，MONTANER J，ARENILLAS J

F，et al. Differential pattern of tissue plasminogen

activator-induced proximal middle cerebral artery

recanalization among stroke subtypes[J]. Stroke，

2004，35（2）：486-490.

[20] ALBERS G W，THIJS V N，WECHSLE L，et al.

Magnetic resonance imaging profiles predict clinical

response to early reperfusion：the diffusion and

perfusion imaging evaluation for understanding

stroke evolution（DEFUSE）study[J]. Ann Neurol，

2006，60（5）：508-517.

[21] MOLINA C A，ALVAREZ-SABIN J. Recanalization

and reperfusion therapies for acute ischemic

stroke[J]. Cerebrovasc Dis，2009，27（Suppl 1）：

162-167.

[22] HEINSIUS T，BOGOUSSLAVSKY J，VAN

MELLE G. Large infarcts in the middle cerebral

artery territory. Etiology and outcome patterns[J].

Neurology，1998，50（2）：341-350.

[23] ZHANG J B，DING Z Y，YANG Y，et al.

Thrombolysis with alteplase for acute ischemic

stroke patients with atrial fibrillation[J]. Neurol Res，

2010，32（4）：353-358.

[24] 刘艳艳，张敏，恽文伟，等. 中重度脑白质疏松对急

性脑梗死静脉溶栓患者出血转化及预后的影响[J].

中华神经科杂志，2017，50（12）：885-891.